Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Posts Increased Revenues, Losses for 2014

NEW YORK (GenomeWeb) – Rosetta Genomics reported today after the close of the market a 228 percent jump in 2014 revenues, derived primarily from the sale of its microRNA-based diagnostics.

The company's revenues from continuing operations jumped to $1.3 million last year from $405,000 the year before.

Rosetta's net loss after discontinued operations was $14.5 million, or $1.29 a share on 11.2 million shares outstanding, versus $12.9 million, or $1.34 a share, on 9.6 million shares outstanding, in 2013.

On a non-GAAP basis, Rosetta's net loss for 2014 was $13.6 million, or $1.21 a share, compared with $12 million, or $1.25 per share, a year earlier.

Rosetta's research and development costs edged up to $1.9 million in 2014 from $1.7 million the year before. Its SG&A costs, meantime, rose to $12.3 million from $11.3 million.

As of December 31, 2014, Rosetta had cash and cash equivalents totaling $7.9 million, versus $16.8 million at the end of 2013.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.